Vical Publication Highlights Milestone in Vaccine Development
SAN DIEGO, Oct. 3, 2013 (GLOBE NEWSWIRE) -- Vical Incorporated (VICL) today announced the publication of a new article1 in a special DNA vaccine issue of the journal Vaccines detailing the development process from initial product concept to Phase 3 trial initiation for ASP0113 (TransVax(TM)), Vical's investigational therapeutic vaccine designed to control cytomegalovirus (CMV) in transplant recipients. Vical and Astellas Pharma Inc. (TSE:4503) ("Astellas") entered into exclusive worldwide license agreements in 2011 to develop and commercialize ASP0113.
"Vical has been a pioneer in the development of DNA vaccines since the discovery of plasmid DNA utility in the late 1980s," said Larry R. Smith, Ph.D., Vice President, Vaccine Research at Vical and lead author of the new publication. "The recent initiation of the Phase 3 trial of ASP0113 marks a major achievement for the company and a significant milestone in the vaccine field. We are particularly pleased to share the recognition for this important 'first' with our partners at Astellas who have assumed responsibility for the advancement of ASP0113. We are excited by the potential to address a serious medical need for immunosuppressed transplant patients whose recovery is threatened by CMV."
The multinational Phase 3 registration trial of ASP0113 was initiated in June 2013 and is expected to enroll approximately 500 hematopoietic cell transplant (HCT) recipients. Astellas is conducting the trial, and Vical is providing development, regulatory and manufacturing support. Astellas expects to begin a separate Phase 2 trial of ASP0113 in solid organ transplant (SOT) recipients later this year.
If this makes Vical closer than any other company to find a vaccine for Herpes.. We should see a hugh increase in Price .. Bought some more today but had to sell my HEB to do it....HEB will now , NOT let us vote on bonus shares,,,,.... BY by HEB Hello Vical.....
Only momentum traders are buying a few hours after any news, not buy & hold investors and bigger players. These traders didn't buy because they saw some sellers are still around. Good news like this article will work for VICL, but not in a very short term.